Stay updated on Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial
Sign up to get notified when there's something new on the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page.

Latest updates to the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.5%
- Check15 days agoChange DetectedDifference0.5%
- Check22 days agoChange DetectedThe webpage has been updated to include new drug information related to Acute Myeloid Leukemia, specifically mentioning Decitabine, Navtemadlin, and Venetoclax, along with their associated clinical trial identifiers. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference51%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from 2025-03-25 to 2025-02-24.SummaryDifference0.5%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3.SummaryDifference0.2%
- Check44 days agoChange DetectedDifference0.3%
Stay in the know with updates to Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page.